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Abstract Objective: We evaluated the adherence to na-
tional guidelines for the treatment of asthma in childhood.
Methods: Prescriptions for anti-asthma medication for
children (0–14 years of age) were retrieved from the
InterAction DataBase (IABD) for the year 2002. These
were compared with recommendations found in national
guidelines. Results: Anti-asthma medication was pre-
scribed for 3,612 children (5%) of the paediatric popula-
tion. Inhaled medication was prescribed for 3,554 (98%)
children. In 1,940 of 1,993 (97%) of the children under the
age of 6 years pressurised metered dose inhalers (pMDIs)
were given. Short-acting β2-agonists had not been pre-
scribed in the previous 2-year period in 559 children
(15%), 543 children older than 8 years (36%) did not receive
a prescription for a dry powder inhalator and 239 children
(7%) had more than one type of inhalator. Long-acting β2-
agonists were prescribed in 396 children, but without
concomitant inhaled corticosteroids (ICS) in 35 children
(9%). Conclusions: Inhalation therapy as the method
of choice in asthma therapy and the use of pMDI in
preschool children are widely accepted in the Netherlands.
Not all children have been prescribed bronchodilators.
Some children have more than one type of inhaler device
and others use long-acting β2-agonists not in combination
with ICS. Although national and international guidelines
about the treatment of asthma in children offer evidence-
based advice, important principles are not followed.
Effective interventions aimed at implementing existing
guidelines into daily practice are urgently needed.
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Introduction
In recent years several guidelines concerning the use of
drugs in children with asthma or asthma-like symptoms
have been published [2, 3, 11, 13]. These guidelines were
developed to help the physician to improve the care for
children with asthma. Whether physicians used these
guidelines (‘adherence’) has been the subject of several
studies. However, these studies concern adherence of
paediatricians [7, 12, 22], focus on the use of inhaler
devices [8], or study a relatively small number of children
[9].
Studies regarding adherence to these recommendations in
a general population are lacking. Insight therein is important
to identify the most common and serious deviations so that it
is possible to develop strategies to improve adherence.
Therefore, we studied the prescription of anti-asthmatic
drugs in a Dutch paediatric population and compared this
with the recommendations found in the Dutch guidelines.
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Methods
In the Netherlands people commonly register with one
pharmacy and obtain all their medication from that phar-
macy, so a complete medication history of each patient is
available in the pharmacy database. Previous studies have
demonstrated that dispensing data from Dutch pharmacies
offer an accurate survey of the use of prescription drugs [14,
16, 18]. Outpatient medication is supplied by community
pharmacies regardless of prescriber and thus included in the
dispensing data, but drugs used during hospital stay
(inpatients) and over-the-counter medication (OTC) are not
included. This study was performed with pharmacy dispens-
ing data from the InterAction DataBase (IADB). The IADB
comprises all prescriptions of approximately 450,000 people
since 1997, regardless of insurance of patients or reimburse-
ment status of the drug [26]. Forty-five pharmacies supplied
dispensing data and prescriptions of at least 200 physicians
are included. It was recently estimated that more than 99% of
the entered prescriptions were collected [27]. Population sizes
were estimated on the basis of age-specific population
statistics (Statistics Netherlands) using a stratified standardi-
sation described elsewhere [21].
Table 1 depicts principles as found in the Dutch guide-
lines. National as well as international guidelines empha-
sise the preference for inhaled medications [2, 11]. Every
child with asthma should have a short-acting bronchodi-
lator (SABA) for direct relief [11]. Long-acting broncho-
dilators (LABA) should be prescribed only in combination
with inhaled corticosteroids (ICS) [11, 30]. For conve-
nience and ease, only one type of inhaler should be
prescribed [31]. In children younger than the age of 7 years,
pressurised metered dose inhalators (pMDIS) with spacer
devices are advised [2, 11, 13]. Different from international
guidelines, in the Netherlands prescription of dry powder
inhalers (DPI) to children older than the age of 7 years is
recommended [13]. Finally, whenever a pMDI is used,
even in older children, it should always be used in
combination with a spacer device. The only exception to
this rule is the Autohaler. In this pMDI the actuation is
dependent on inspiratory flow. The guidelines were pub-
lished in the national medical journal and in the journal of
the Dutch College of General Practitioners [10, 13]. After
publication numerous seminars and symposia in which the
guidelines were explained and discussed were organised.
Medications were defined according to the Anatomical
Therapeutic Chemical (ATC) classification [4]. Asthma
medication was defined as short- (SABA) and long-acting
bronchodilators (LABA), including long-acting bronchodi-
lators combined with inhaled steroids (ATC code R03A),
inhaled corticosteroids (R03B), adrenergics for systemic use
(R03C), leucotriene receptor antagonists (LTRA) (R03D),
and two oral antihistaminics [deptropine (R06AX16) and
ketotifen (R06AX17)]. Ketotifen and deptropine are drugs
that were traditionally used in the Netherlands for the
treatment of young children with asthmatic symptoms.
Table 1 Principles in medical asthma treatment according to the Dutch guidelines
1 Every child with asthma should use at least one inhaled medication
2 Every child should have been prescribed a short-acting β2-agonist in the preceding 2 years
3 Every child with a long-acting β2-agonist should have inhaled corticosteroids as well
4 Every child should have to use only one type of inhalation device. The only exception to this is when a child uses a pMDI with a short-
acting β2-agonist
5 Children <6 years should have a pressurised metered dose inhaler pMDI and spacera
6 Children >8 years should have a dry powder inhalator (DPI)a
7 Pressurised metered dose inhalers (pMDIs) should always be used in combination with a spacer, or it should be an Autohaler
aFor the study of the use of inhalation devices, children between the age of 6 and 8 years were excluded because in those ages children
change from pMDI with spacer to a dry powder inhalator
Table 2 Asthma medication
and inhalation devices, used in
the Dutch paediatric population
during the study period [4]
Medications ATC code
Short-acting bronchodilators: salbutamol, terbutaline, fenoterol R03A
Long-acting bronchodilators: salmeterol, formoterol R03A
Inhaled steroids: beclomethasone, budesonide, fluticasone R03B
Other inhaled drugs: ipratropium bromide, R03B
Cromoglicic acid, nedocromil R03B
Adrenergics for systemic use: salbutamol, terbutaline R03C
Leucotriene receptor antagonist: montelukast R03D
Antihistamines for systemic use: deptropine, ketotifen R06AX16/17
Inhalation devices
Pressurised metered dose inhaler single: Autohaler
Pressurised metered dose inhaler in combination with spacers
Spacer devices: Babyhaler, Volumatic, Nebuhaler, Aerochamber, and Babychamber
Dry powder inhalers: Diskus, Diskhaler, Turbuhaler, Cyclocaps
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Table 2 depicts the asthma medication and inhaler devices
available in the Netherlands in 2002. These were available
for all patients, regardless of their reimbursement.
For this study, all children aged 0–14 years on 31
December 2001 were identified and selected from the
database. For every child included in the study a medication
history from 1 January to 31 December 2002 was
constructed. We included only children for whom we
knew for sure that we had information during the study
period. When a child had been prescribed any asthma
medication in 2002, the complete history of anti-asthma
medications of the previous 2 years prior to the first pre-
scription date in 2002 was retrieved. This was done because
all inhaled medication expires 2 years after dispension. In
children younger than the age of 2 years, the medication
prescribed since birth was retrieved. For the evaluation of
the number of inhalers prescribed we excluded children with
a DPI who also had pMDI with a spacer device for
inhalation of a reliever, such as salbutamol, because some
children prefer the use of these during attacks.
For the study of inhalation devices, children between the
age of 6 and 8 years were excluded because in those ages
children change from pMDI with spacer to a dry powder
inhalator. The 95% confidence intervals were calculated
using the Wilson method as recommended elsewhere [1].
Results
In 2002 about 450,000 patients were covered by the
database; of these 73,416 were 14 years of age or younger.
In this age group 3,612 children (4.9%) had been
prescribed anti-asthma medication. These prevalences
were compared with data of the national Drug Information
Project and no statistically or clinically significant differ-
ences were found (data not shown). Table 3 summarises the
results of the comparison between actual daily practice and
principles in medical asthma treatment.
The vast majority of these children (3,554; 98%) received
prescriptions for inhaled medications. In 559 children (15%)
no SABA was prescribed during the observation period of
2 years. In 498 of these 559 children (89%) ICS had been
prescribed in 2002. In the total group of 3,612 children on
asthma medication, 396 (11%) had been prescribed LABA,
while 35 (9%) of them had not received a prescription for an
inhaled corticosteroid as well. After exclusion of the chil-
dren who had been prescribed a pMDI containing SABA, it
appeared that 239 of 3,217 children (7%) had been pre-
scribed more than one type of inhalation device.
Of the 1,993 children younger than 6 years 53 (3%) had
been prescribed a dry powder inhaler, the youngest child
was only 2 years old. Of the 1,525 children older than
8 years 982 (64%) had been prescribed a dry powder in-
halator (DPI), the remaining 36% had a pMDI.
Spacers had been provided to 1,783 of the 2,761 children
(64.6%) who had been prescribed a pMDI. Thus, the re-
maining 978 children (35.4%) had a pMDI without a spacer
or had a spacer older than 2 years.
Overall, when the recommendations except the pre-
scription of spacer devices are applied, it appeared that of
the 3,612 children on asthma medication 2,352 (65.1%)
children were prescribed medication according to the
recommendations.
Discussion
Although we did not expect a 100% adherence to all guide-
lines, we found that in one-third of the children who
received asthma medication basic recommendations were
not followed. It is striking that 4.9% of the children in this
population received a prescription for asthma medication
and 15% of these children did not receive a prescription for
bronchodilators. Nine percent of the children who had been
prescribed a LABA did not have any ICS and 7% received
prescriptions for more than one type of inhalation device.
This study has some limitations. The diagnosis of asthma
was not formally confirmed and therefore it could be that
some children received asthma medication for other in-
dications. However, in the Netherlands only doctors pre-
scribe asthma medication. Because we looked at dispensing
data, we have no insight into actual use of asthma med-
ication. Finally, as a result of the method, we have no
information about the prescribing physician.
The strong points of this study are that it provides
detailed information in a relatively large group of patients
in a country where general physicians and paediatricians
have easy access to specific guidelines. Inevitably, some of
the recommendations in the Dutch guidelines differ from
those in other countries, e.g. the use of DPI in children
Table 3 Prescription of asthma
medication compared with
evidence-based principles. CI
confidence interval
Principle Children (n) Nonadherence
n % (CI)
1 Inhaled medication for all 3,612 58 1.6 (1.2–2.1)
2 β2-agonists for all 3,612 559 15.5 (14.3–16.7)
3 LABA combined with ICS 396 35 8.8 (6.4–12.0)
4 Only one type of inhalera 3,217 239 7.4 (6.6–8.4)
5 pMDI for children <6 years 1,993 53 2.7 (2.0–3.5)
6 DPI for children >8 years 1,525 543 35.6 (33.2–38.0)
7 pMDI prescribed in combination use with a spacerb 2,761 978 35.4 (33.7–37.2)
aExcept for β2-agonists
bExcept for Autohaler
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older than the age of 8 years. However, for an evaluation
of adherence to guidelines this is not problematic.
Five percent of the children in this total population had
received a prescription for asthma medication. This per-
centage is comparable with results of a German study in
which the prevalence of asthma drug usage was 4.8% in 9-
to 11-year-old children [6], but is lower than in a recent
British survey in which 20% of 9-year-old children used
asthma medication [19]. The prevalence of children with
anti-asthmatic medication is lower than the reported prev-
alence of asthma and/or recurrent wheezing in Western
countries, which varies between 10 and 20% [17, 25]. The
size of the paediatric population was estimated, and al-
though this estimation may be slightly off, it by no means
explains the low prevalence we have found. All available
asthma medication in the Netherlands was included in this
study. Possible explanations for the low figure include
underdiagnosis of asthma, undertreatment of diagnosed
asthma, and the choice of alternative or non-pharmacologi-
cal asthma treatments or overestimation of asthma preva-
lence in epidemiological studies. Alternatively, it could be
that the prevalence of asthma is declining, as was suggested
recently by Van Schayck [28]. The preferential use of inhaled
medication appears to be adopted by Dutch physicians as
98% of the children received inhaled medications. Because
children younger than the age of 5 cannot generate sufficient
inspiratory flow to achieve optimal deposition while using a
DPI [20], it is reassuring that 97% of the children under the
age of 6 received prescriptions for a pMDI.
Several deviations from guidelines were found. Fifteen
percent of the children had not been prescribed a reliever in
the preceding 2 years, whilst in 89% of these children ICS
were prescribed. Although it has been suggested to give a
course of ICS in periodical viral wheeze in young infants
[5], this was not recommended formally in 2002, nor
common practice in the Netherlands. Dispension of drugs
by hospital pharmacies is not customary in the Netherlands,
due to budgetary reasons, and therefore cannot be an
explanation. The fact that 15% of the children do not have a
reliever may implicate that in these patients asthma is
completely under control with the use of ICS and that
relievers are not or rarely needed. Current guidelines advise
the tapering of inhaled steroids to the minimum effective
dose or even to discontinue them [11]. Apparently, some
children continue to use ICS despite minimal disease.
LABA are advised only in combination with ICS because
they can mask ongoing symptoms and do not treat the
underlying inflammation in asthma [30]. In this study it
appeared that despite this, 9% of the children on LABA had
no ICS.
The relatively high number of 239 (7%) of children with
more than one type of inhaler device is comparable with
results of a British study in which 12% of the children used
more than one type of inhaler [8]. A proper inhalation
technique is essential but difficult to retain. In a recent
Dutch study it was found that in 29% of children with a
DPI, the technique was insufficient [15]. The use of more
than one type of inhaler, and therefore two different
inhalation techniques, is confusing and should therefore be
dissuaded [31].
Different from other guidelines, the Dutch guidelines
advise DPIs in children older than the age of 7 years,
because it is believed that DPIs are more convenient to use
and easier to take, e.g. at school and sports [10, 13].
Therefore we included this element in the study. Thirty-six
percent of the children older than 8 years did not have a
DPI. An explanation could be that some children cannot
inhale properly. Another explanation for not using a DPI in
this age group is that the use of medication is not checked
on a regular basis and therefore the children continue to use
pMDIs.
pMDIs should be used with a spacer [2, 3, 11, 13]. It
appeared that 65% of the children with a pMDI had
received such a spacer device in the preceding 2 years and
35% had not received a spacer device. An explanation
could be that the spacers have been in use for a longer
period, but it is also possible that some children have no
spacer at all.
Possible reasons for not following recommendations are
lack of knowledge or non-accessibility to guidelines. In
both the national and international literature, guidelines
have been published and these publications were readily
available to all Dutch physicians, so this cannot be the
reason. It has been suggested that sometimes guidelines do
not rely on evidence [22]. This cannot explain the non-
adherence in this study because the principles studied do
rely on evidence. It could be argued that not all guidelines
are applicable to all patients. However, the high number of
children not treated according to principles makes this
unlikely.
Lack of adherence to guidelines is recognised in treat-
ment of asthma in children [7–9, 12, 22], as well as in
adults [23, 29]. Several interventions, aimed at the pre-
scribing physicians, such as computer-assisted flow sheets,
peer group training, and electronic medical records have
been studied. Although every intervention has some
beneficial effects, none has proven conclusive [23, 29].
Nonadherence could be explained by the fact that
children with asthma are not seen on a regular basis and
their medication is not checked properly. In the Nether-
lands it is customary that patients or their parents send the
label of the medication used to the general practitioner,
who will provide a repeat prescription without a consul-
tation visit. In this way, patients can receive medications
for a long period without being seen by a doctor.
It has been stressed that a health care provider should
support patients with asthma to ensure optimal care [11]. A
regular check is essential to tailor the treatment to the needs
of the patient. Therefore, sending in labels for a repeat
prescription of asthma medication should be discouraged.
Pharmacists can compare the prescriptions of asthma
medication with current recommendations. When a devi-
ation occurs, the pharmacists should inform the prescribing
physician. In the treatment of patients with hypertension
the involvement of pharmacists improved clinical outcome
[24].
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In conclusion, although almost all children with asthma
medication received a prescription for inhaled medication,
not all children have a reliever, and not all children who use
a LABA have had a prescription for ICS. Some children
have more than one type of inhalator. Apparently, there is
still a wide gap between guidelines and daily practice,
despite the availability and reliability of guidelines.
Probably other methods have to be sought for ensuring
asthma treatment according to guidelines. Attention to
prescribed medication by pharmacists could be one of these
methods.
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